search button

MicroRNA-133b is regulated by TAp63 while no gene mutation is present in colorectal cancer

  • Authors:
    • Yifei Chen
    • Yi Zhang
    • Jianhuai He
    • Ying Fu
    • Changwei Lin
    • Xiaorong Li

  • View Affiliations

  • Published online on: January 16, 2017     https://doi.org/10.3892/or.2017.5371
  • Pages: 1646-1652
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Downregulation of miR-133b has been reported in multiple types of malignancies including colorectal cancer (CRC). We previously confirmed that TAp63 actively translates microRNA-133b (miR-133b) transcripts. While the presence of miRNA mutations have frequently been described in CRC, most CRCs do not show any variation in the miR‑133b coding sequence. Therefore, it is important to elucidate the relationship between TAp63 and miR-133b, and identify other mediators of miR-133b downregulation in CRC. The expression of TAp63 was detected by RT-qPCR, western blotting, immunohistochemistry (IHC) and densitometric analysis using Image-Pro Plus 6.0 software in 38 CRC and corresponding non-cancerous tissues (NCTs). The expression of mature miR‑133b was determined by RT-qPCR, in situ hybridization (ISH) and densitometric analysis using Image-Pro Plus 6.0 software. The DNA from 38 CRC tissues and NCTs were screened for miR-133b mutations through sequence analysis. Compared with the NCTs, TAp63 mRNA expression was significantly lower in 21 (55.27%) tumor tissues. Compared with the NCTs, the miR‑133b expression level was significantly lower in 31 (81.58%) tumor tissues. The expression of miR‑133b was found to be positively correlated with TAp63. Loss of TAp63 and miR-133b was associated with an increased likelihood of metastatic events. The area under the ROC curve (AUC) of TAp63 for CRC was 0.623 [95% confidence interval (CI), 0.497-0.748; P=0.046], with 73.7% sensitivity and 50% specificity, respectively. The AUC of miR-133b for CRC was 0.857 (95% CI, 0.774‑0.940; P<0.0001), with 78.9% sensitivity and 81.6% specificity, respectively. The combined AUC of TAp63 and miR-133b for CRC was 0.881 (95% CI, 0.805-0.956; P<0.0001), with 89.5% sensitivity and 71.1% specificity, respectively. Point mutations within the seed region of miR-133b were found in 1 patient, but the point mutation did not impact the secondary structure of the pre-miR-133b. Therefore, downregulation of TAp63 may be one reason for the dysregulation of miR‑133b in CRC. The expression analysis of TAp63 and miR-133b revealed that they may be used as valuable prognostic biomarkers for CRC.
View Figures
View References

Related Articles

Journal Cover

March-2017
Volume 37 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 3.8
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 8.5
  • CiteScore Rank: Q1: #74/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.719
  • SCImago Journal Rank (SJR): 0.864
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Chen Y, Zhang Y, He J, Fu Y, Lin C and Li X: MicroRNA-133b is regulated by TAp63 while no gene mutation is present in colorectal cancer. Oncol Rep 37: 1646-1652, 2017.
APA
Chen, Y., Zhang, Y., He, J., Fu, Y., Lin, C., & Li, X. (2017). MicroRNA-133b is regulated by TAp63 while no gene mutation is present in colorectal cancer. Oncology Reports, 37, 1646-1652. https://doi.org/10.3892/or.2017.5371
MLA
Chen, Y., Zhang, Y., He, J., Fu, Y., Lin, C., Li, X."MicroRNA-133b is regulated by TAp63 while no gene mutation is present in colorectal cancer". Oncology Reports 37.3 (2017): 1646-1652.
Chicago
Chen, Y., Zhang, Y., He, J., Fu, Y., Lin, C., Li, X."MicroRNA-133b is regulated by TAp63 while no gene mutation is present in colorectal cancer". Oncology Reports 37, no. 3 (2017): 1646-1652. https://doi.org/10.3892/or.2017.5371